OMT-28
OMT-28 is an investigational therapy. This means it is still being tested in clinical trials. It is not approved for use anywhere.
Manufacturer
Omeicos Therapeutics GmbH
Types of mito
Primary mitochondrial disease with muscle or heart symptoms.
Which people with mito might this therapy help?Â
People with primary mitochondrial disease who have muscle symptoms, heart symptoms, or both.
This may include people with:
- MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
- MERFF (myoclonus epilepsy with ragged-red fibers)
- mitochondrial myopathy
- mitochondrial cardiomyopathy
- other mitochondrial DNA changes.
It is designed to target pathways linked to inflammation, cell protection and mitochondrial function.
Researchers are studying whether it can help improve mitochondrial energy production and physical function in people with primary mitochondrial disease.
What research has been done on this therapy?Â
OMT-28 has been tested in a Phase 2a study. This study included people with primary mitochondrial disease who had myopathy, cardiomyopathy, or both.
The study enrolled 29 people across 9 expert sites in Germany, Italy and the Netherlands. Participants had a 12-week period without treatment, then took OMT-28 once a day for up to 24 weeks.
The manufacturer has reported that the therapy has had positive results.
Important information
Find out more
Emerging therapies for mito
Learn about developing therapies and opportunities to take part in research.
Clinical trials explained
A guide to help understand participation and make informed decisions.
